|
|
Article: Twice-Weekly Administered Anti-Angiogenic Troponin Shows Unusually Potent Effect in Suppression of Experimental Tumor Metastases.
- Article from:
- Business Wire
- Article date:
- March 15, 1999
CopyrightCOPYRIGHT 1999 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOSTON--(BW HealthWire)--March 15, 1999--
Report in Proceedings of the
National Academy of Sciences
Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that twice-weekly, relatively low dosages of its anti-angiogenic protein, Troponin I, which had previously been shown to inhibit primary cancers in animals, significantly suppressed experimental lung metastases in a rigorous animal model of metastatic melanoma. These results, as well as other scientific findings related to the discovery of the anti-angiogenic properties of Troponin I, are to be published tomorrow in the Proceedings of the National Academy of Sciences (PNAS).
The ...
Related newspaper, magazine, and journal articles:
|
|
Article: Boston Life Sciences Moves into New ...
Business Wire;
September 13, 2005 ;
700+ words
...HOPKINTON, Mass. -- Boston Life Sciences, Inc. (NASDAQ: BLSI ... numbers are as follows: Boston Life Sciences, Inc. 85 Main Street Hopkinton ... bostonlifesciences.com About Boston Life Sciences Boston Life Sciences, Inc ...
|
|